Verastem opens phase II study of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer Dec. 1, 2020
Braftovi and Mektovi approved in Japan for additional indication of BRAF-mutant colorectal cancer Dec. 1, 2020
ValiRx presents full updated data from its phase I/II study of VAL-201 in prostate cancer Dec. 1, 2020
DAY-101 well tolerated, shows antitumor activity in patients with recurrent low-grade glioma Nov. 30, 2020
RSS